

Prognostic Value of Long Noncoding RNA NORAD in Various cancers: a meta-analysis

Qin Yang ^{a, b, 1}, Zheng Zhang ^{c, 1}, Yuan-Yuan Gong ^{a, b, 1}, Zhi-Ran Li ^{a, b}, Hua-Zhu

Zhang ^{a, b}, Gong-Hao He ^{a, b, *}

^a *Research Center of Clinical Pharmacology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming 650032, China.*

^b *Department of Pharmacy, 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd., Kunming 650032, China.*


^c *Medical Engineering Section, The 306th Hospital of PLA, Beijing 100101, China.*

Running title: lncRNA NORAD with prognosis of cancer patients

¹ These authors contributed equally to this work.

* Correspondence to: Gong-Hao He, Ph.D., 212 Daguan Rd, Kunming 650032, China.

Tel: +86-871-64774793, E-mail: gonghow@hotmail.com.



Supplementary Figure S2. The expression levels of NORAD in seven kinds of cancer tissues and normal tissues.

“*” indicates a log₂FC value > 1 and *P*-value < 0.01.

Abbreviations: CHOL: Cholangiocarcinoma; DLBC: Lymphoid neoplasm diffuse large b-cell lymphoma; KICH: Kidney Chromophobe; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and Paraganglioma; PEAD: Rectum adenocarcinoma; THYM: Thymoma.